Assessment of Progranulin and FAM19A5 Protein Blood Levels in Metabolic Syndrome

Assessment of Progranulin and Chemokine-like Protein TAFA-5 (FAM19A5) Blood Levels in Adults With Metabolic Syndrome

The main objective of the study is to assess the serum levels of progranulin and FAM19A5 protein in adults with metabolic syndrome.

The study is planned to be conducted on 40 adults with metabolic syndrome. As a control, it is planned to recruit 40 adults without metabolic syndrome. From all participants fasting venous blood samples, urine samples and hair samples will be collected. Next, serum progranulin and serum FAM19A5 protein concentrations will be determined in both groups. Also, serum concentration of leptin, vascular endothelial growth factor (VEGF), insulin, neopterin, adropin and selected cytokines, adipokines, myokines and chemokines, total cholesterol, low-density lipoproteins, high-density lipoproteins, triglycerides and glucose will be determined. Serum, hair and urine mineral content will be determined. In whole blood genetic analyses will be performed in order to detect and examine progranulin and FAM19A5 genes, and genes associated with the development of metabolic syndrome and genes associated with the body's mineral metabolism. Also, body composition analysis, blood pressure measurement, pulse measurement, blood oxygen saturation measurement and nutritional interview will be performed.

Inclusion Criteria:

• written and informed consent of the participant to participate in the study;

• age 18-99;

• meeting at least three of the following five metabolic syndrome criteria:

  • waist circumference ≥80 cm in women and ≥94 cm in men;
  • serum triglycerides> 150 mg / dl (1.7 mmol / l) or treatment of hypertriglyceridemia;
  • HDL serum concentration <50 mg / dl (1.3 mmol / l) - in women and <40 mg / dl (1.0 mmol / l) - in men or treatment of this lipid disorder;
  • systolic blood pressure ≥ 130 mm Hg or diastolic blood pressure ≥ 85 mm Hg, or treatment of previously diagnosed hypertension;
  • fasting plasma glucose ≥100 mg / dl (5.6 mmol / l) or pharmacological treatment of type 2 diabetes.

Exclusion Criteria:

• secondary form obesity,
• substitution of progranulin or / and FAM19A5 protein,
• weight reduction above 5% of baseline body weight in the last 3 months preceding recruitment,
• liposuction and / or other fat reduction treatments,
• pacemaker, cardioverter / defibrillator,
• condition after stroke,
• Alzheimer's disease,
• fronto-temporal dementia,
• occurrence of other neurodegenerative diseases,
• occurrence of significant neurological disorders,
• occurrence of inflammatory autoimmune diseases,
• lysosomal storage diseases,
• clinically significant abnormal liver, kidney or thyroid function;
• acute or clinically significant inflammatory process in the respiratory, digestive, genitourinary tracts,
• connective tissue diseases or arthritis;
• active cancer,
• addiction to alcohol or drugs;
• pregnancy or childbirth during recruitment or 3 months before recruitment;
• current lactation or lactation within 3 months before recruitment;
• and / or any other condition which, according to researchers, would cause that participation would not be in the patient's best interest or could limit the credibility of the study